They all had severe disease and a high treatment burden with an average of 10 injections with Eylea (aflibercept), a widely-used VEGF inhibitor sold by Bayer and Regeneron, in the last 12 months.

Results from a trial comparing three treatments for serious eye disease have shown that Regeneron and Bayer's Eylea is the most effective. The trial was sponsored by the US government-funded ...

Flattening sales in the Eylea ophthalmology franchise were more than offset by strong sales from immunology drug Dupixent and oncology drug Libtayo. Despite strong competitive pressures facing the ...

This arrangement, the lawsuit claims, effectively lowered Eylea's selling price and provided Regeneron with a competitive advantage in the anti-VEGF medication market. The Department of Justice ...